GlassScriptPhysician profile
Richard S Schloss
NPI 1992856660
$22,143.15
in general payments reported to CMS, 2019-2025
36 companies · $3,109 in 2025
The $3,109 reported for 2025 was more than what 93% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,441 · 2020: $2,238 · 2021: $2,985 · 2022: $4,222 · 2023: $4,251 · 2024: $2,897 · 2025: $3,109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,257.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $2,410.23 | 2019-2025 | Rexulti |
| Abbvie INC. | $2,372.98 | 2021-2025 | Vraylar |
| Teva Pharmaceuticals USA, INC. | $2,311.73 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,220.42 | 2020-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $1,741.19 | 2019-2025 | Trintellix |
| Alkermes, INC. | $1,552.38 | 2022-2025 | Lybalvi, Aristada |
| Neurocrine Biosciences, INC. | $1,507.60 | 2019-2025 | Ingrezza |
| Lundbeck LLC | $1,119.31 | 2019-2025 | Rexulti |
| Axsome Therapeutics, INC. | $1,099.43 | 2022-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $895.95 | 2019-2025 | Spravato |
| Supernus Pharmaceuticals, INC. | $580.27 | 2021-2023 | Qelbree |
| Sunovion Pharmaceuticals INC. | $453.15 | 2019-2021 | |
| Allergan, INC. | $371.98 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $362.14 | 2020-2024 | Jornay Pm |
| Corium, LLC | $333.52 | 2022-2025 | Azstarys |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Schloss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.